



SAFETY DATA SHEET

Revision date 16-Aug-2022

Version 1.01

Page 1 / 12

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Product Code(s) PZ03249
Trade Name: Atropine Sulfate Injection, USP
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as Anticholinergic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements

Signal word Not Classified

Hazard statements Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Additional information For a more detailed discussion of potential health hazards and toxicity see Section 11.

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 2 / 12
Version 1.01

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified as hazardous	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 0.5%≤C<2% Skin Corr. 1A :: C≥5% Skin Corr. 1B :: 2%≤C<5% Skin Irrit. 2 :: 0.5%≤C<2%	No data available	No data available
+ Sulfuric acid (CAS #: 7664-93-9)	**	-	231-639-5	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 5%≤C<15% Skin Corr. 1A :: C≥15% Skin Irrit. 2 :: 5%≤C<15%	No data available	No data available
Atropine sulfate, monohydrate (CAS #: 5908-99-6)	0.01	-	200-235-0	Acute Tox. 2 (H300) Acute Tox. 2 (H330)	Not Listed	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

No information available

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Sodium hydroxide	325	1350	No data available	No data available	No data available

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 3 / 12
Version 1.01

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
1310-73-2					
+ Sulfuric acid 7664-93-9	2140	No data available	0.375	No data available	No data available
Atropine sulfate, monohydrate 5908-99-6	500	No data available	No data available	No data available	No data available

Additional information

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin contact	Remove contaminated clothing and wash exposed area with soap and water. Obtain medical assistance if irritation occurs.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media As for primary cause of fire.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Not applicable.

Hazardous combustion products Formation of toxic gases is possible during heating or fire. May include oxides of carbon and products of nitrogen

5.3. Advice for firefighters

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 4 / 12
Version 1.01

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing mist or aerosols. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Atropine sulfate, monohydrate

Pfizer OEL TWA-8 Hr: 4 µg/m³

SODIUM CHLORIDE

Latvia

5 mg/m³

Russia

MAC: 5 mg/m³

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 5 / 12
Version 1.01

Sodium hydroxide

ACGIH OEL (Ceiling)	2 mg/m ³
ACGIH TLV	Ceiling: 2 mg/m ³
Austria	2 mg/m ³
	STEL 4 mg/m ³
Bulgaria	2.0 mg/m ³
Czech Republic	1 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³
Estonia	1 mg/m ³
	STEL: 2 mg/m ³
Finland	Ceiling: 2 mg/m ³
France	2 mg/m ³
Hungary	1 mg/m ³
	STEL: 2 mg/m ³
Ireland	STEL: 2 mg/m ³
Ceiling Limit Value	2 mg/m ³
Latvia	0.5 mg/m ³
Poland	STEL: 1 mg/m ³
	0.5 mg/m ³
Romania	1 mg/m ³
	STEL: 3 mg/m ³
Slovakia	2 mg/m ³
Spain	STEL: 2 mg/m ³
Switzerland	2 mg/m ³
	STEL: 2 mg/m ³
OSHA PEL	2 mg/m ³
	(vacated) Ceiling: 2 mg/m ³
United Kingdom	STEL: 2 mg/m ³

+ Sulfuric acid

ACGIH TLV	0.2 mg/m ³
Austria	0.1 mg/m ³
	STEL 0.2 mg/m ³
Bulgaria	0.05 mg/m ³
Czech Republic	1 mg/m ³
	0.05 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	0.05 mg/m ³
Estonia	0.05 mg/m ³
European Union	TWA: 0.05 mg/m ³
Finland	0.05 mg/m ³
	STEL: 0.1 mg/m ³
France	0.05 mg/m ³
Germany	0.1 mg/m ³
	Ceiling / Peak: 0.1 mg/m ³
Germany	0.1 mg/m ³
Hungary	0.05 mg/m ³
Ireland	0.05 ppm
	STEL: 0.15 ppm
Italy	0.05 mg/m ³
Ceiling Limit Value	1 mg/m ³
Latvia	0.05 mg/m ³
Netherlands	0.05 mg/m ³
Poland	0.05 mg/m ³
Romania	0.05 mg/m ³
Russia	MAC: 1 mg/m ³
	Skin
Slovakia	0.05 mg/m ³
Spain	0.05 mg/m ³
Switzerland	0.1 mg/m ³

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 6 / 12
Version 1.01

OSHA PEL

United Kingdom

STEL: 0.2 mg/m³
1 mg/m³
(vacated) TWA: 1 mg/m³
TWA: 0.05 mg/m³
STEL: 0.15 mg/m³

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls

No information available.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state

Liquid

Color

Colorless

Odor

No information available.

Odor threshold

No information available

Molecular formula

Mixture

Molecular weight

Mixture

Property

Values

pH

4.2 (3.0-6.5)

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 7 / 12
Version 1.01

Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	Soluble
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

Oxidizing properties

None

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

Hazardous polymerization Will not occur.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials None.

10.6. Hazardous decomposition products

Hazardous decomposition products Thermal decomposition products include oxides of carbon, nitrogen, and sulfur.

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 8 / 12
Version 1.01

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Short term	May cause central nervous system effects.
Known Clinical Effects:	Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety and dilated pupils. Cases of severe overdose may lead to respiratory depression.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

+ Sulfuric acid

Rat Oral LD50 2140 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Atropine sulfate, monohydrate

Rat Oral LD50 500-600 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Sulfuric acid	= 2140 mg/kg (Rat)	-	= 0.375 mg/L (Rat) 4 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

+ Sulfuric acid

Eye Irritation Rabbit Severe

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Atropine sulfate, monohydrate

100 Day(s) Rabbit Intramuscular 44 mg/kg/day LOAEL Male reproductive system, Gallbladder

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 9 / 12
Version 1.01

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Atropine sulfate, monohydrate

Embryo / Fetal Development Oral 50 mg/kg LOAEL Developmental toxicity, Maternal toxicity
Embryo / Fetal Development Rat Not Teratogenic
Embryo / Fetal Development Dog LOEL Not Teratogenic
Reproductive & Fertility-Females Rat Subcutaneous 200 mg/kg LOEL Fertility
Reproductive & Fertility Rat Oral 62.5 mg/kg NOAEL Fertility
Embryo / Fetal Development Mouse Subcutaneous 50 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Atropine sulfate, monohydrate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Atropine sulfate, monohydrate

2 Year(s) Rat Intraperitoneal Not carcinogenic

Carcinogenicity

The International Agency for Research on Cancer (IARC) and the United States National Toxicology Program (NTP) have classified 'occupational exposure to strong inorganic acid mists containing sulfuric acid' as a known human carcinogen. This classification applies only to sulfuric acid when generated as a mist. This classification is debated within the scientific community and there is disagreement as to whether or not a cause and effect relationship between cancer and 'occupational exposure to strong inorganic acid mists containing sulfuric acid' exists.

+ Sulfuric acid

IARC
NTP

Group 1 (Carcinogenic to Humans)
Known Human Carcinogen

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 10 / 12
Version 1.01

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Sulfuric acid	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable
Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water
CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
 Revision date 16-Aug-2022

Page 11 / 12
 Version 1.01

EINECS	231-791-2
AICS	Present
SODIUM CHLORIDE	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present
Sodium hydroxide	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
+ Sulfuric acid	
CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	1000 lb
California Proposition 65	carcinogen 3/14/2003
TSCA	Present
EINECS	231-639-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 6
Atropine sulfate, monohydrate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 2 Schedule 4

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Sulfuric acid - 7664-93-9	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

SAFETY DATA SHEET

Product Name Atropine Sulfate Injection, USP (Adult) (Hospira Inc.)
Revision date 16-Aug-2022

Page 12 / 12
Version 1.01

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Acute toxicity, inhalation-Cat.2; H330 - Fatal if inhaled Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage Reproductive toxicity-Cat.2; H361fd - Suspected of damaging fertility. Suspected of damaging the unborn child

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reason for revision Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date 16-Aug-2022

Prepared By Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.